• Elise Landais 2017
  • 11.9.17AtlanticLivePharm287 slider
  • tcell 620x305
  • Janssen Syringe
  • MSD Fellows Fade Black
  • devin slider homepage
  • IAVI STUDY IN IMMUNITY
    MAPS POWERFUL
    ANTIBODY DEVELOPMENT
    IN STUDY VOLUNTEER

    Read more
  • FRAN PRIDDY
    TALKS SCIENTIFIC
    CHALLENGES
    AT VACCINE EVENT
    HOSTED BY
    THE ATLANTIC

    Read more
  • IAVI EXPLORES
    HIV-CANCER LINK

    Jonathan Hare at the Human Immunology Lab
    in London is teaming up with cancer scientists
    to investigate immunological similarities
    between cancer and HIV.

    Read more
  • IAVI CLINICAL NETWORK HELPS
    JANSSEN ASSESS PROMISING
    MOSAIC HIV VACCINE

    Read more
  • IAVI PARTNERS WITH
    MSD FELLOWS TO
    IMPROVE HIV
    PREVENTION

    Read more


  • UNEXPECTED COW ANTIBODY
    RESEARCH PUBLISHED
    IN NATURE


    Read more

A Vaccine is Essential to a World Without AIDS Thumbnail

For Scientists

The Journal of AIDS Vaccine Research

IR Vol21No3 2017 Cover border2Decisive Moments in Wake of Paris
Like the development of the antibodies themselves, understanding and optimizing immunogens designed to elicit a broadly neutralizing response against HIV takes time. Read more

Most Recent Publications

Science for Non-Scientists

VAX has AIDS vaccine science for you.

VAX 1116 masthead

Annual Investment Trends in HIV Prevention Research and Development

Global preventive AIDS vaccine R&D investment totaled US$818 million in 2013, with the public sector providing US$666 million (81%), the philanthropic sector providing US$121 million (15%), and the commercial sector contributing US$31 million (4%). The 2013 total investment represents a decrease of US$29 million (4%) below global preventive AIDS vaccine R&D investment in 2012.

Continue Reading